Phoenix, AZ — bioSyntagma, LLC announced today that the United States Patent and Trademark Office fully issued patent # 15/099,121 for “Method and Apparatus for Extracting and Collecting Single Cells from Formalin-Fixed Paraffin Embedded Tissues,” which bioSyntagma has exclusively licensed from Arizona Technology Enterprises (AzTE). This patent is the foundational technology for the company’s unique […]
In the News
January 6, 2017 Phoenix, AZ — bioSyntagma, LLC, a developer of life science tools for single and multi-cell analysis announced today it has been has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant of $213,904 to conduct basic research and development, (R&D). The aims of this grant are to further […]
September 20th, 2016 bioSyntagma Developing New Microfluidic Tool for Processing Formalin Fixed Paraffin Embedded (FFPE) and Frozen Tissue Specimens for in-situ Genomics Applications, to Present Poster # 207 “Novel ‘Tiling’ Method for Heterogeneity Detection in FFPE samples” at 2016 Advances in Genome Biology and Technology Personalized Health Conference Scottsdale, AZ — bioSyntagma, LLC., a developer of […]
About this project
Join us in making cancer research faster and more informative. bioSyntagma has developed a device that enables researchers and drug developers to get closer to making personalized medicine a reality by studying drug resistance in cancer patients.